Stem Cell Therapy for Duchenne Muscular Dystrophy

What This Article Covers

Duchenne muscular dystrophy (DMD) is a severe, progressive genetic condition that primarily affects boys, gradually weakening skeletal and heart muscle from early childhood. While most headlines about "new DMD treatments" concern gene therapy (such as Elevidys), a separate and genuinely promising line of research uses cell therapy — most notably cardiosphere-derived cells (CAP-1002, now known as deramiocel) from Capricor Therapeutics. This page focuses specifically on that cell-based approach: how it's thought to work, what the clinical trial evidence actually shows, and where things stand with the FDA as of this writing.

How It's Thought to Work

DMD is caused by mutations in the dystrophin gene, which leave muscle cells — including heart muscle — without a protein that normally protects them from damage during contraction. Over time this leads to chronic inflammation, muscle fiber death, and replacement of muscle with scar and fatty tissue, affecting roughly 1 in 3,500 to 5,000 boys born, according to the Muscular Dystrophy Association (MDA).

Deramiocel does not fix the underlying genetic defect. Instead, it's an allogeneic (donor-derived) cardiosphere-derived cell product, given by repeated intravenous infusion, that appears to work indirectly — by calming chronic inflammation and supporting the body's own regenerative signaling in both heart and skeletal muscle. Researchers describe this as an "anti-inflammatory, pro-regenerative" mechanism rather than a cure, and it's designed to be used alongside, not instead of, standard DMD therapies like corticosteroids.

What the Evidence Shows

The evidence here is more mature than for most experimental DMD approaches, and some of it is genuinely encouraging. In the placebo-controlled Phase 2 HOPE-2 trial, published in The Lancet, cardiosphere-derived cell therapy slowed decline in upper-limb function by about 71% relative to placebo on a key motor measure (p=0.01), with a full Performance of Upper Limb score also favoring treatment (p=0.04) and a meaningful improvement in cardiac ejection fraction versus control (p=0.002) — a rare double signal, touching both the arms and the heart, in a disease that steadily takes both.

The larger, pivotal Phase 3 HOPE-3 trial (106 participants, 20 U.S. sites) built on that promise: Capricor announced in December 2025 that deramiocel met its primary endpoint, showing a 54% slowing of upper-limb function decline versus placebo (p=0.029), plus a 91% slowing of ejection fraction decline on a key cardiac endpoint (p=0.041), with no new safety concerns over the 12-month study.

That said, this program's regulatory path has been genuinely bumpy, and that matters for setting expectations. The FDA accepted Capricor's Biologics License Application with Priority Review in 2025 but issued a Complete Response Letter in July 2025, declining to approve it and requesting more efficacy data and manufacturing clarification. Capricor then submitted the full HOPE-3 study report and refined its proposed indication toward preserving upper-limb function; even so, the FDA's Cellular, Tissue and Gene Therapies Advisory Committee voted 9-3 in July 2026 that available evidence did not support effectiveness, with reviewers calling parts of the data "fragile" and disputing which statistical analysis plan should govern the review. As of this writing, deramiocel is not FDA-approved for DMD; the agency's target decision date has been pushed to November 2026 after Capricor submitted additional 24-month extension data. In short: real, replicated signals of benefit exist, but regulators have not yet been convinced they're strong enough to approve.

Who Might Be a Candidate

Outside of clinical trials or expanded access, deramiocel is not currently an approved or generally available treatment. The trial populations to date have generally included:

• Boys and young men with a confirmed DMD diagnosis, both ambulatory and non-ambulatory
• Patients already on stable background therapy, such as corticosteroids
• Patients with measurable upper-limb or cardiac (ejection fraction) impairment being tracked as trial endpoints
• Individuals enrolled through a research center participating in Capricor's ongoing studies or open-label extensions, not through a private clinic

Families should be very cautious of any clinic outside a registered clinical trial offering "stem cell treatment for Duchenne" — no cell therapy is currently FDA-approved for this disease, and unregulated stem cell clinics have a documented history of overpromising results.

Bottom Line

Cardiosphere-derived cell therapy is one of the more scientifically grounded cell-based approaches being studied for Duchenne muscular dystrophy, with two separate placebo-controlled trials showing statistically significant slowing of both upper-limb and cardiac decline. That is a legitimately hopeful signal in a disease with few options that touch the heart at all. But hope is not the same as approval: the FDA has twice declined to clear deramiocel in its current form, and its own advisory committee recently voted against it, reflecting real scientific disagreement about how strong and reliable the data are. For now, this remains an investigational therapy, not a cure, and not something available outside of clinical research. Families should discuss any interest in trial enrollment with their child's neuromuscular specialist and treat unauthorized "stem cell" offers for DMD with serious skepticism.